A controlled study of double filtration plasmapheresis in the treatment of active rheumatoid arthritis

Journal of Clinical Rheumatology

Volumn 13, Issue 4, 2007, Pages 193-198

  Yu, Xiaoxia ^a   Ma, Jinrong ^a   Tian, Junge ^a   Jiang, Shunua ^a   Xu, Ping ^a   Han, Heping ^a   Wang, Lixin ^a  

^a Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine   (China)

Author keywords

Double filtration plasmapheresis; Rheumatoid arthritis

Indexed keywords

METHOTREXATE; SALAZOSULFAPYRIDINE;

ADULT; AGED; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE COURSE; DRUG EFFICACY; FEMALE; FOLLOW UP; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; MAJOR CLINICAL STUDY; MALE; PLASMAPHERESIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; STATISTICAL SIGNIFICANCE; WEAKNESS;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; PLASMAPHERESIS; QUALITY OF LIFE; RECOVERY OF FUNCTION; SULFASALAZINE; TREATMENT OUTCOME;

EID: 34548459782     PISSN: 10761608     EISSN: None     Source Type: Journal    
DOI: 10.1097/RHU.0b013e318124a483     Document Type: Article

References (39)

1. Jiang M, Yu D, Lin X, et al. ZhongHua Rheumatology. China: Huaxia Publisher; 2004:697-827.
2. Rheumatoid of ZhongHua Medical Association. Guideline for Rheumatoid Arthritis. J Zhonghua Rheumatol. 2003;7:250-254.
3. Odeh M. New insights into the pathogenesis and treatment of rheumatoid arthritis. Clin Immunol Immunopathol. 1997;83:103-116.
4. Wolfe F, Rehman Q, Lane N, et al. Starting a disease modifying antirheumatic drug or a biologic agent in rheumatoid arthritis: standards of practice for RA treatment. J Rheumatol. 2001;28:1704-1711.
5. Weinblatt ME. The role of current strategies in the future treatment of rheumatoid arthritis. Rheumatology. 1999;38:19-23.
6. Mokrzycki MH, Kaplan AA. Therapeutic plasma exchange: complications management. Am J Kidney Dis. 1994;23:817-827.
7. Okada H, Moriwaki K, Sugahara S, et al. Comparative study of clinicale effects between plasma adsorption and double filtration plamapheresis in patients with myasthenia gravis. Ther Apher. 1997;1:343-347.
8. Ghodrat A, Siami, Siami SF. Membrane plasmapheresis in the United States: a review over the last 20 years. Ther Apher. 2001;5:315-320.
9. Rothwell RS, Davis P, Gordon PA, et al. A controlled study of plasma exchange in the treatment of severe rheumatoid arthritis. Arthritis Rheum. 1980;23:785-790.
10. Jaffe IA. Comparison of the effect of plasmapheresis and penicillamine on the level of circulating rheumatoid facter. Ann Rheum Dis. 1963;22:71-76.
11. Yeh JH, Chiu HC. Double filtration plasmapheresis in myasthenia gravis-analysis of clinical efficacy and prognostic parameters. Acta Neurol Scand. 1999;100:305-309.
12. Ravichandran P, Nataraj T, Jaganath C. Splenic radiation and double-filtration plasmapheresis in crossmatch-positive live renal transplantation. Transplant Proc. 2005;37:1806-1807.
13. Otsubo S, Tanabe K, Shinmura H, et al. Effect of post-transplant double filtration plasmapheresis on recurrent focal and segmental glomerulosclerosis in renal transplant recipients. Ther Apher Dial. 2004;8:299-304.
14. Tanabe K, Tokumoto T, Ishida H, et al. ABO-incompatible renal transplantation at Tokyo Women's Medical University. Clin Transpl. 2003;16:175-81.
15. Cheng BC, Chang WN, Chen JB, et al. Long-term prognosis for Guillain-Barre syndrome: evaluation of prognostic factors and clinical experience of automated double filtration plasmapheresis. J Clin Apher. 2003;18:175-180.
16. Lyu RK, Chen WH, Hsieh ST. Plasma exchange versus double filtration plasmapheresis in the treatment of Guillain-Barre syndrome. Ther Apher. 2002;6:163-166.
17. Chen WH, Yeh JH, Chiu HC. Experience of double filtration plasmapheresis in the treatment of Guillain-Barre syndrome. J Clin Apher. 1999;14:126-129.
18. Yeh JH, Chen WH, Huang KM, et al. Prethymectomy plasmapheresis in myasthenia gravis. J Clin Apher. 2005;20:217-221.
19. Chiu HC, Yeh JH, Chen WH. Pulmonary function study of myasthenia-gravis patients treated with double-filtration plasmapheresis. J Clin Apher. 2003;18:125-128.
20. Kimura K, Tsuda H, Kwangseok Y, et al. Study of plasma levels of soluble CD40 ligand in systemic lupus erythematosus patients who have undergone plasmapheresis. Ther Apher Dial. 2005;9:64-68.
21. Chiu H-C, Chen W-H, Yey J-H. Year experience plasmapheresis in patients with myasthenia gravis. Ther Apher. 2000;4:291-295.
22. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 1988;31:315-324.
23. Maini RN, Breedveld FC, Kalden JR, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum. 2004;50:1051-1065.
24. Dougados M, Combe B, Cantagrel A, et al. A Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis. 1999;58:220-225.
25. Drossaers-Bakker KW, de Buck M, van Zeben D, et al. Long-term course and outcome of functional capacity in rheumatoid arthritis: the effect of disease activity and radiologic damage over time. Arthritis Rheum. 1999;42:1854-1860.
26. Welsing P, van Gestel A, Swinkels H, et al. The relationship between disease activity, joint destruction, and functional capacity over the course of rheumatoid arthritis. Arthritis Rheum. 2001;44:2009-2017.
27. Fries J, Spitz P, Young D. The dimensions of health outcome: the health assessment questionnaire, disability, and pain scores. J Rheumatol. 1982;9:789-793.
28. Ware JJ, Sherbourne C. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473-483.
29. Wells G, Tugwell P, Kraag G, et al. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. J Rheumatol. 1993;20:557-560.
30. Redelmeier D, Lorig K. Assessing the clinical importance of symptomatic improvements: an illustration in rheumatology. Arch Intern Med. 1993;153:1337-1342.
31. Wolfe F. A reappraisal of HAQ disability in rheumatoid arthritis. Arthritis Rheum. 2000;43:2751-2761.
32. Wolfe F. The burden of rheumatoid arthritis: based on a presentation by Frederick Wolfe, MD. Am J Manag Care. 1999;5(suppl 14):s852-s859.
33. Pincus T, Callahan L. Remodeling the pyramid or remodeling the paradigms concerning rheumatoid arthritis: lessons from Hodgkin's disease and coronary artery disease. J Rheumatol. 1990;17:1582-1585.
34. Klippel JH, Crofford LJ, et al. Primer on the rheumatic diseases. Atlanta, GA: Arthritis Foundation; 2001:209-232.
35. Yeh J-H, Chen W-H, Chiu H-C, et al. Clearance studies during subsequent sessions of double filtration plasmapheresie. Artif Organs. 2006;30:111-114.
36. Yeh J-H, Chen W-H, Chiu H-C. Complications of double-filtration plasmapheresis. Transfusion. 2004;44:1621-1625.
37. Hatano Y, Katagiri K, Arakawa S, et al. Successful treatment by double-filtration plasmapheresis of a patient with bullous pemphigoid: effects in vivo on transcripts of several genes for chemokines and cytokines in peripheral blood mononuclear cells. Br J Dermatol. 2003;148:573-579.
38. Liu J, Zhang C, Li W, et al. Double filtration plasmapheresis for the treatment of rheumatoid arthritis: a study of 21 cases. Artif Organs. 1997;21:96-98.
39. Matsuda Y, Tsuda H, Takasaki Y, et al. Double filtration plasmapheresis for the treatment of a rheumatoid arthritis patient with extremely high level of C-reaction protein. Ther Apher Dial. 2004;8:404-408.